The loan agreement with the European Investment Bank (EIB) grants Oncopeptides access to a renewed unsecured loan facility of up to EUR 30 million. The loan facility agreement is divided into three tranches, each with a maturity of five years, which will become available if the company, inter alia, satisfies certain milestones related to the ongoing commercialization of Pepaxti® in Europe and a potential relaunch of Pepaxto® in the US. In connection with the loan agreement, Oncopeptides has entered into a renewed warrant agreement with the EIB, entitling the EIB to warrants in the company should the company draw on the loan facility.
Oncopeptides is a biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company´s lead product is approved on several markets for treatment of adult patients with multiple myeloma. The company’s shares are admitted to trading on Nasdaq Stockholm.
Vinge’s team has consisted of Louise Brorsson Salomon, Arvid Weimers and Kamyar Najmi (finance) as well as Dain Hård Nevonen and Linnéa Sellström (capital markets).
